Clinical Trial Update: Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating trabectedin in ovarian cancer patients with BRCA1/BRCA2 mutations or BRCAness phenotype; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Trabectedin (trabectedin)

Snippet

Sponsor: Catholic University of the Sacred Heart | Conditions: BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype | Phase 2 | Status: UNKNOWN